NASHVILLE, Tenn. / Nov 15, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:
Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel)
November 19, 2024
1x1 Meetings Only
BTIG 4th Annual Ophthalmology Day (Virtual)
December 2, 2024
1x1 Virtual Meetings Only
Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace)
December 3-5, 2024
Company will host a Fireside Chat at 8:00 a.m. ET on December 4, 2024
The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. Only the Piper Sandler conference will include an audio webcast, which will be available on the Company’s website.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$31.36 |
Daily Change: | -0.39 -1.23 |
Daily Volume: | 352,744 |
Market Cap: | US$1.120B |
May 14, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load